Clinical Trial Update: Evaluation of Alirocumab in Addition to Lipid-Modifying Therapy in Patients With High Cardiovascular Risk and Hypercholesterolemia in South Korea and Taiwan [Phase 3]

View source ↗

Summary

This is a Phase 3 trial evaluating alirocumab added to lipid-modifying therapy in high cardiovascular risk patients with hypercholesterolemia in South Korea and…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypercholesterolemia

Drugs mentioned

• Alirocumab (Praluent) (alirocumab)

Snippet

Sponsor: Sanofi | Conditions: Hypercholesterolemia | Phase 3 | Status: COMPLETED | Results posted: 2017-06-26